Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Vericiguat et indices de remodelage inverse dans l'insuffisance cardiaque (VERI-PATH)

24 septembre 2026 mis à jour par: Gregor Poglajen, University Medical Centre Ljubljana

Effets du Vériciguat sur les Indices de Remodelage Inverse : Approche Physiopathologique du Traitement de l'Insuffisance Cardiaque avec Fraction d'Éjection Réduite

The goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy.

The main questions are:

  • Does vericiguat improve right ventricular systolic function, measured by fractional area change (FAC)?
  • Does vericiguat favourably influence myocardial remodeling, fibrosis, angiogenesis, inflammation, metabolism, renal function, and hematologic balance?
  • Do genetic and oxidative stress profiles modify treatment response? Researchers will compare a group receiving vericiguat plus usual care with a group receiving usual care alone to assess structural, functional, and biomarker changes over 12 months.

Participants will:

  • Have blood drawn at baseline and follow-up visits for biomarker, metabolomic, genetic, transcriptomic, and hematologic analyses, including platelet function testing
  • Perform oral glucose tolerance tests (OGTT) to assess insulin resistance
  • Undergo echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy to evaluate heart structure, function, and perfusion
  • Attend follow-up visits at 1, 3, 6, and 12 months Open-label extension: After the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This exploratory extension will reassess study outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort.

Aperçu de l'étude

Description détaillée

Heart failure with reduced ejection fraction (HFrEF) involves pathologic processes that lead to maladaptive remodeling of the myocardium with ventricular dilation, wall thickening, and cellular and microvascular changes that progressively worsen cardiac function. Many established therapies for heart failure can promote reverse remodeling, improving symptoms and long-term outcomes.

Vericiguat is a soluble guanylate cyclase (sGC) stimulator that increases cyclic guanosine monophosphate (cGMP), a signaling molecule with vasodilatory and cardioprotective effects that is impaired in heart failure. Randomized trials show that vericiguat reduces the risk of worsening heart-failure events in HFrEF after recent decompensation, and emerging evidence indicates that these benefits extend to stable HFrEF. The mechanisms by which vericiguat may benefit patients with HFrEF remain incompletely understood.

Preclinical data suggest that augmenting cGMP signaling may confer antifibrotic, antihypertrophic, antiinflammatory, proangiogenic, and metabolic effects. These mechanisms could contribute to reverse remodeling and improved clinical status, but they require confirmation in a clinical setting.

This randomized, controlled study will evaluate the effects of vericiguat on right ventricular systolic function, assessed by fractional area change (FAC), and will characterize associated structural and biologic changes in adults with stable HFrEF on contemporary GDMT. Sixty participants will be randomized to vericiguat plus usual care or to usual care alone and followed for 12 months, with study visits at 1, 3, 6, and 12 months.

At each visit, blood samples will be collected for analysis of circulating biomarkers reflecting fibrosis, inflammation, angiogenesis, renal function, and metabolism, as well as transcriptomic profiling. Comprehensive metabolomic profiling will be performed, and insulin resistance will be evaluated by oral glucose tolerance testing (OGTT) at baseline and 12 months. Hematologic parameters will be measured at each visit, while platelet function will be assessed at baseline and 12 months.

Cardiac structure and function will be assessed using transthoracic echocardiography, cardiac magnetic resonance imaging, and cardiac scintigraphy. Imaging will quantify biventricular volumes, systolic function, fibrosis, and perfusion.

The study will investigate whether cumulative oxidative stress and genetic variation modify the response to vericiguat. Cumulative oxidative stress will be quantified from serial 8-hydroxy-2'-deoxyguanosine (8-OHdG) measurements (area under the curve) and examined for interaction with treatment effects on TAPSE and other outcomes. Genetic analyses will assess variants in drug-disposition and NO-sGC-cGMP pathway genes for associations with response.

After completing the 12-month randomized phase, participants originally assigned to usual care will be offered open-label vericiguat and followed for an additional 12 months. This non-randomized, exploratory extension will re-measure the randomized-phase outcomes to evaluate the consistency and magnitude of response to vericiguat in the prior control cohort, using Month 12 values as the extension baseline.

Overall, this research is designed to clarify the pathophysiologic mechanisms of vericiguat therapy in HFrEF and to support more personalized treatment strategies for patients living with heart failure.

Type d'étude

Interventionnel

Inscription (Estimé)

70

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Izola, Slovénie, 6310
        • Recrutement
        • Division of Internal Medicine, Izola General Hospital
        • Contact:
          • Tinkara Ravnikar, MD
          • Numéro de téléphone: +386 5 6606 000
          • E-mail: info@sb-izola.si
      • Ljubljana, Slovénie, 1000
        • Recrutement
        • University Medical Centre Ljubljana
        • Contact:
        • Contact:
        • Sous-enquêteur:
          • Tine Bajec, MD
        • Chercheur principal:
          • Gregor Poglajen, MD, PhD
        • Sous-enquêteur:
          • Gregor Zemljič, MD, PhD
        • Sous-enquêteur:
          • Andraž Cerar, MD, PhD
        • Sous-enquêteur:
          • Miran Šebeštjen, MD, PhD
        • Sous-enquêteur:
          • Neža Žorž, MD
        • Sous-enquêteur:
          • Sabina Frljak, MD, PhD
        • Sous-enquêteur:
          • Renata Okrajšek, MD, PhD
        • Sous-enquêteur:
          • Sabina Ugovšek, MD
        • Sous-enquêteur:
          • Petra Girandon Sušanj, MD
      • Ljubljana, Slovénie, 1000
        • Recrutement
        • Clinical Department of Vascular Diseases, University Medical Centre Ljubljana
        • Contact:
          • Borut Jug, MD
          • Numéro de téléphone: +386 (01) 522 80 11
          • E-mail: borut.jug@kclj.si
      • Maribor, Slovénie, 2000
        • Recrutement
        • University Department of Cardiology and Angiology, University Medical Centre Maribor
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Written informed consent from an adult patient (≥ 18 years old) to participate in the clinical study,
  • Stable HFrEF defined as no heart failure worsening in the 6 months before randomization that required hospitalization or outpatient diuretic treatment,
  • Confirmed diagnosis of chronic heart failure with reduced ejection fraction (LVEF < 50%, confirmed by echocardiography) within 12 months before randomization,
  • Stable GDMT for HFrEF for at least 3 months prior to randomisation.

Exclusion Criteria:

  • Systolic blood pressure < 100 mmHg or symptomatic hypotension,
  • Current or planned use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type V inhibitors,
  • Known allergy/hypersensitivity to soluble guanylate cyclase stimulators,
  • Awaiting heart transplantation or dependence on continuous inotropic therapy
  • Cardiac amyloidosis, sarcoidosis, myocarditis, stress cardiomyopathy, or tachycardic cardiomyopathy,
  • Acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention in the past three months before randomisation,
  • Long-term mechanical circulatory support of the left ventricle,
  • Active infection,
  • Chronic kidney disease stage 4 or 5, and
  • Advanced liver failure classified as Child-Pugh B or C.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Vericiguat + GDMT

Participants will receive vericiguat added to guideline-directed medical therapy (GDMT) for heart failure. Vericiguat will be initiated at 2.5 mg once daily and up-titrated in approximately 2-week intervals to 5 mg and then a target dose of 10 mg once daily, as tolerated, over the 12-month randomized phase.

Oral soluble guanylate cyclase stimulator administered once daily, initiated at 2.5 mg and up-titrated in approximately 2-week intervals to 5 mg and then 10 mg as tolerated, in addition to guideline-directed medical therapy for heart failure.

Autres noms:
  • MK-1242
  • Verquvo

Standard combination heart failure therapy according to current guidelines (ARNI, beta-blocker, MRA, and SGLT2 inhibitor as tolerated).

Autres noms:
  • GDMT
Comparateur actif: GDMT

Participants will continue to receive guideline-directed medical therapy (GDMT) for heart failure without vericiguat during the 12-month randomized phase (vericiguat offered during exploratory extension).

Standard combination heart failure therapy according to current guidelines (ARNI, beta-blocker, MRA, and SGLT2 inhibitor as tolerated).

Autres noms:
  • GDMT

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in right ventricular systolic function assessed by right ventricular fractional area change (RV FAC)
Délai: Baseline to 6 months and 12 months

Change in RV FAC (%), measured by transthoracic echocardiography (TTE) in the apical four-chamber view.

Baseline to 6 months and 12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in left ventricular systolic function assessed by left ventricular ejection fraction (LVEF)
Délai: Baseline to 6 months and 12 months

Change in LVEF (%), measured by transthoracic echocardiography using 2D biplane Simpson's method.

Baseline to 6 months and 12 months
Change in left ventricular systolic function assessed by left ventricular global longitudinal strain (GLS)
Délai: Baseline to 6 months and 12 months

Change in left ventricular GLS (%), measured by transthoracic echocardiography using speckle-tracking.

Baseline to 6 months and 12 months
Change in left ventricular structure assessed by left ventricular mass index (LVMI)
Délai: Baseline to 6 months and 12 months

Change in LVMI (g/m²), calculated from transthoracic echocardiography using the Devereux formula and indexed to body surface area.

Baseline to 6 months and 12 months
Change in right ventricular systolic function assessed by tricuspid annular plane systolic excursion (TAPSE)
Délai: Baseline to 6 months and 12 months

Change in TAPSE (mm), measured by transthoracic echocardiography in the apical four-chamber view using M-mode.

Baseline to 6 months and 12 months
Change in circulating serum fibrosis biomarkers assessed by Galectin-3 (Gal-3) and soluble ST2 (sST2)
Délai: Baseline, 1 month, 3 months, 6 months, and 12 months

Change in serum Gal-3 (ng/mL) and sST2 (ng/mL) concentrations, measured in peripheral blood samples.

Baseline, 1 month, 3 months, 6 months, and 12 months
Change in serum angiogenetic biomarkers assessed by angiogenesis-related biomarker panel composite score
Délai: Baseline, 1 month, 3 months, 6 months, and 12 months

Change in angiogenesis-related biomarker panel composite score, measured using a Luminex multiplex immunoassay (Human XL Cytokine Luminex® Performance Assay 46-plex).

Baseline, 1 month, 3 months, 6 months, and 12 months
Change in systemic inflammation assessed by serum inflammatory biomarker panel composite score
Délai: Baseline, 1 month, 3 months, 6 months, and 12 months

Change in serum inflammatory biomarker panel composite score, measured using a Luminex multiplex immunoassay (Human XL Cytokine Luminex® Performance Assay 46-plex).

Baseline, 1 month, 3 months, 6 months, and 12 months
Change in cardiac fibrosis assessed by the extent of late gadolinium enhancement (LGE)
Délai: Baseline to 12 months

Change in extent of myocardial LGE (% of left ventricular mass), quantified by cardiac magnetic resonance (CMR).

Baseline to 12 months
Change in myocardial microvascular dysfunction assessed by quantitative myocardial perfusion scintigraphy
Délai: Baseline to 12 months

Change in myocardial blood flow (MBF, mL/min/g), measured by quantitative myocardial perfusion scintigraphy.

Baseline to 12 months
Change in insulin sensitivity assessed by the Matsuda index
Délai: Baseline and 12 months

Change in insulin sensitivity measured by the Matsuda index (unitless), derived from a standard 75-g oral glucose tolerance test (OGTT).

Baseline and 12 months
Change in kidney function assessed by urine albumin-to-creatinine ratio (UACR)
Délai: Baseline, 1 month, 3 months, 6 months, and 12 months

Change in UACR (mg/g), measured from a spot urine sample.

Baseline, 1 month, 3 months, 6 months, and 12 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Difference in right ventricular systolic function assessed by right ventricular fractional area change (RV FAC) between genotype groups
Délai: Genotyping at baseline; RV FAC change from baseline to 12 months

Difference in change in RV FAC (%), measured by transthoracic echocardiography, between patients with wild-type vs mutated UGT1A9 gene, assessed by genotyping/sequencing from peripheral blood samples.

Genotyping at baseline; RV FAC change from baseline to 12 months
Change in pre-specified gene set expression score, assessed by peripheral blood RNA-seq
Délai: Baseline, 1 month, 3 months, 6 months, and 12 months

Change in expression score of a pre-specified gene set (unitless normalized RNA-seq expression score), assessed by peripheral blood RNA sequencing (RNA-seq).

Baseline, 1 month, 3 months, 6 months, and 12 months
Difference in right ventricular systolic function assessed by right ventricular fractional area change (RV FAC) between high versus low oxidative stress groups
Délai: Time Frame: 8-OHdG at baseline, 1 month, 3 months, 6 months, and 12 months; RV FAC change from baseline to 12 months

Difference in change in RV FAC (%), measured by transthoracic echocardiography, between participants with high versus low oxidative stress defined by the median of the 12-month urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) area-under-the-curve (AUC, ng/mL·month), measured by validated immunoassay.

Time Frame: 8-OHdG at baseline, 1 month, 3 months, 6 months, and 12 months; RV FAC change from baseline to 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Chercheur principal: Gregor Poglajen, MD, PhD, Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 novembre 2025

Achèvement primaire (Estimé)

31 juillet 2027

Achèvement de l'étude (Estimé)

31 décembre 2027

Dates d'inscription aux études

Première soumission

22 novembre 2025

Première soumission répondant aux critères de contrôle qualité

8 février 2026

Première publication (Réel)

12 février 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Deidentified individual participant data (IPD) that underlie the results reported in future publications (text, tables, figures, and appendices) will be shared upon reasonable request. Shared IPD will include baseline characteristics, outcome measures, and relevant biomarker data, excluding data that could compromise participant privacy or institutional confidentiality.

Délai de partage IPD

IPD will be made available within 6 months after publication of the main results and will remain accessible for at least 5 years thereafter.

Critères d'accès au partage IPD

Researchers whose proposed use of the data is approved by the principal investigator will be granted access. Proposals should include a concise research plan and statistical analysis outline. Requests should be submitted to tine.bajec@kclj.si. Approved requesters will sign a data sharing agreement to ensure data confidentiality and appropriate use.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner